Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans

NeuroReport

Volumn 25, Issue 13, 2014, Pages 1018-1023

  Yardley, Megan M ^a   Neely, Michael ^c   Huynh, Nhat ^b   Asatryan, Liana ^b   Louie, Stan G ^a,b   Alkana, Ronald L ^a   Davies, Daryl L ^b  

^a Department of Pharmacology and Pharmaceutical Sciences ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

alcohol use disorders; alcoholism therapy; drug repositioning; medications development

Indexed keywords

ALCOHOL; CENTRAL DEPRESSANT AGENT; DRINKING WATER; DRUGS USED IN THE TREATMENT OF ADDICTION; IVERMECTIN;

ANALYSIS OF VARIANCE; ANIMAL; BLOOD ANALYSIS; BODY WEIGHT; BRAIN; C57BL MOUSE; DECISION MAKING; DRINKING BEHAVIOR; DRUG EFFECTS; DRUG THERAPY; FOOD PREFERENCE; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; TANDEM MASS SPECTROMETRY;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ANALYSIS OF VARIANCE; ANIMALS; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; BRAIN; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHOICE BEHAVIOR; CHROMATOGRAPHY, LIQUID; DRINKING BEHAVIOR; DRINKING WATER; ETHANOL; FOOD PREFERENCES; IVERMECTIN; MALE; MICE, INBRED C57BL; TANDEM MASS SPECTROMETRY;

EID: 84905969523     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000211     Document Type: Article

References (32)

1. Johnson B. Medication treatment of different types of alcoholism. Am J Psychiatry 2010; 167:630-639.
2. Grant BF, Dawson DA, Stinson FS, Chou P, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004; 74:223-234. (Pubitemid 38759777)
3. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD. Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med 2011; 41:516-524.
4. Naimi TS. The cost of alcohol and its corresponding taxes in the U.S.: a massive public subsidy of excessive drinking and alcohol industries. Am J Prev Med 2011; 41:546-547.
5. World Health Organization. Global status report on alcohol and health; 2011. http://www.who.int/substance-abuse/publications/global-alcohol- report/msbgsruprofiles.pdf.
6. Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the veterans health administration. Psychiatr Serv 2010; 61:392-398.
7. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 2012; 17:513-527.
8. Edlund MJ, Booth BM, Han X. Who seeks care where? Utilization of mental health and substance use disorder treatment in two national samples of individuals with alcohol use disorders. J Stud Alcohol Drugs 2012; 73:12.
9. Geary TG. Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol 2005; 21:530-532. (Pubitemid 41447026)
10. Molinari G, Soloneski S, Larramendy ML. New ventures in the genotoxic and cytotoxic effects of macrocyclic lactones, abamectin and ivermectin. Cyogenet Genome Res 2010; 128:37-45.
11. Jelinkova I, Yan Z, Liang Z, Moonat S, Teisinger J, Stojilkovic SS, Zemková H. Identification of P2X4 receptor-specific residues contributing to the ivermectin effects on channel deactivation. Biochem Biophys Res Commun 2006; 349:619-625. (Pubitemid 44344563)
12. Khakh BS, Bao XR, Labarca C, Lester HA. Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds. Nature Neurosci 1999; 2:322-330. (Pubitemid 30491274)
13. Silberberg SD, Li M, Swartz KJ. Ivermectin interaction with transmembrane helices reveals widespread rearrangements during opening of P2X receptor channels. Neuron 2007; 54:263-274. (Pubitemid 46561201)
14. Asatryan L, Popova M, Woodward JJ, King BF, Alkana RL, Davies DL. Roles of ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and P2X3 receptors. Neuropharmacol 2008; 55:835-843.
15. Popova M, Asatryan L, Ostrovskaya O, Wyatt LR, Li K, Alkana RL, Davies DL. A point mutation in the ectodomain-transmembrane 2 interface eliminates the inhibitory effects of ethanol in P2X4 receptors. J Neurochem 2010; 112:307-317.
16. Asatryan L, Popova M, Perkins D, Trudell JR, Alkana RL, Davies DL. J Pharmacol Exp Ther 2010; 334:720-728.
17. Yardley M, Wyatt L, Khoja S, Asatryan L, Ramaker MJ, Finn DA, et al. Ivermectin reduces alcohol intake and preference in mice. Neuropharmacology 2012; 63:190-201.
18. Asatryan L, Yardley MM, Khoja S, Trudell JR, Huynh N, Louie SG, et al. Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders. Int J Neuropsychopharmacol 2014; 17:907-916.
19. Wyatt LR, Finn DA, Khoja S, Yardley MM, Asatryan L, Alkana RL, et al. Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice. Neurochem Res 2014; 39:1127-1139.
20. Blednov YA, Ozburn AR, Walker D, Ahmed S, Belknap JK, Harris RA. Hybrid mice as genetic models of high alcohol consumption. Behav Genet 2010; 40:93-110.
21. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002; 42:1122-1133.
22. Trailovic AM, Trailovic N. Central and peripheral neurotoxic effects of ivermectin in rats. J Vet Med Sci 2010; 73:591-599.
23. Merck, Sharp, Dohme. Poision control monograph. Ivermectin. Pennsylvania, USA: Division of Merck and Co Ltd WP; 1988.
24. Takougang I, Ngogang J, Sihom F, Ntep M, Kamgno J, Eyamba A, et al. Does alcohol consumption increase the risk of severe adverse events to ivermectin treatment? Afr J Pharm Pharmacol 2008; 2: 77-82.
25. McClearn GE. The genetics of mouse behavior in novel situations. J Compar Physiol Psychol 1959; 52:62-67.
26. Rodgers DA. Research activities related to treatment of alcoholism. Compr Psychiatr 1966; 7:57-67.
27. Belknap JK, Crabbe JC, Young ER. Voluntary consumption of ethanol in 15 inbred mouse strains. Psychopharmacology (Berl) 1993; 112:503-510. (Pubitemid 23324174)
28. Middaugh LD, Kelley BM, Bandy AL, McGroarty KK. Ethanol consumption by C57BL/6 mice: influence of gender and procedural variables. Alcohol 1999; 17:1 75-183.
29. Yoneyama N, Crabbe JC, Ford MM, Murillo A, Finn DA. Voluntary ethanol consumption in 22 inbred mouse strains. Alcohol 2008; 42: 149-160.
30. Bortolato M, Yardley M, Khoja S, Godar SC, Asatryan L, Finn DA, et al. Pharmacological insights into the role of P2x4 receptors in behavioral regulation: lessons from ivermectin. Int J Neuropsychopharmacol 2013; 16:1059-1070.
31. Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008; 31:91-98.
32. Crump A, Omura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87:13-28.